CN119365455A - 对溴结构域有活性的化合物 - Google Patents

对溴结构域有活性的化合物 Download PDF

Info

Publication number
CN119365455A
CN119365455A CN202380043848.XA CN202380043848A CN119365455A CN 119365455 A CN119365455 A CN 119365455A CN 202380043848 A CN202380043848 A CN 202380043848A CN 119365455 A CN119365455 A CN 119365455A
Authority
CN
China
Prior art keywords
methyl
pyridine
dihydrofuro
quinolin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380043848.XA
Other languages
English (en)
Chinese (zh)
Inventor
G·P·史密斯
S·拉斯特
L·P·斯塔西
J·佩罗卡塔基亚
V·博雅克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuevolution AS
Original Assignee
Nuevolution AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuevolution AS filed Critical Nuevolution AS
Publication of CN119365455A publication Critical patent/CN119365455A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380043848.XA 2022-04-19 2023-04-19 对溴结构域有活性的化合物 Pending CN119365455A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2250473 2022-04-19
SE2250473-2 2022-04-19
PCT/US2023/019121 WO2023205251A1 (en) 2022-04-19 2023-04-19 Compounds active towards bromodomains

Publications (1)

Publication Number Publication Date
CN119365455A true CN119365455A (zh) 2025-01-24

Family

ID=86331094

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380043848.XA Pending CN119365455A (zh) 2022-04-19 2023-04-19 对溴结构域有活性的化合物

Country Status (8)

Country Link
US (1) US20250382308A1 (enExample)
EP (1) EP4511119A1 (enExample)
JP (1) JP2025514712A (enExample)
CN (1) CN119365455A (enExample)
AU (1) AU2023255396A1 (enExample)
CA (1) CA3255932A1 (enExample)
MX (1) MX2024013002A (enExample)
WO (1) WO2023205251A1 (enExample)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476260B2 (en) 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2496580B1 (en) 2009-11-05 2013-12-11 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
SI2496582T1 (sl) 2009-11-05 2016-04-29 Glaxosmithkline Llc Corporation Service Company Benzodiazepinski inhibitor bromodomene
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
US20150344444A1 (en) 2012-12-20 2015-12-03 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroxyquinoxalinones
CN105229002A (zh) 2012-12-20 2016-01-06 拜耳医药股份有限公司 抑制bet蛋白的二氢吡啶并吡嗪酮
ES2896400T3 (es) 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
CA3048602A1 (en) * 2016-12-27 2018-07-05 Fujifilm Corporation Antitumor agent and bromodomain inhibitor

Also Published As

Publication number Publication date
US20250382308A1 (en) 2025-12-18
EP4511119A1 (en) 2025-02-26
WO2023205251A1 (en) 2023-10-26
CA3255932A1 (en) 2023-10-26
MX2024013002A (es) 2024-11-08
AU2023255396A1 (en) 2024-10-24
JP2025514712A (ja) 2025-05-09

Similar Documents

Publication Publication Date Title
KR20250070059A (ko) 신규한 테트라헤테로사이클 화합물
KR102429419B1 (ko) Rho-키나아제 억제제로서 티로신 아마이드 유도체
KR101864561B1 (ko) Jak 억제제
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
CN111712499A (zh) 一种atr抑制剂及其应用
TW202102509A (zh) 靶向prmt5之化合物
HK1223100A1 (zh) 杂环化合物
MX2014008605A (es) Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
CA3253533A1 (en) GLP-1R MODULATOR COMPOUNDS
CA2956871A1 (en) Compounds active towards bromodomains
EP3768272B1 (en) Jak inhibitors
CN109721600B (zh) 一类含氮稠环化合物及其制备方法和用途
EP4736854A2 (en) Heterocyclic compounds as modulators of bcl6 as ligand directed degraders
JP2022554385A (ja) Ｗｄｒ５阻害剤及び調節剤
CA3234693A1 (en) Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
WO2020001449A1 (zh) 作为IRAK4抑制剂的异噻唑并[5,4-d]嘧啶类化合物
EP3692026B1 (en) Benzofuran derivatives and their use as bromodomain inhibitors.
ES2987429T3 (es) Derivados de 4-(7h-pirrolo[2,3-d]pirimidin-4-il)-3,6-dihidropiridin-1-(2h)-carboxamida como inhibidores de cinasas limk y/o rock para su uso en el tratamiento del cáncer
AU2023255396A1 (en) Compounds active towards bromodomains
WO2011078226A1 (ja) 三環系化合物
CN117126136B (zh) Parp7抑制剂及其应用
EP3028703B1 (en) Piperidine derivatives as wnt signaling inhibitor
CN110229157A (zh) 嘧啶并五元芳香杂环类化合物、其制备方法及用途
HK40113255A (zh) 取代的直链螺环衍生物
WO2026055780A1 (en) Compounds and compositions for treating mc4r related conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination